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Background-—Limited data are available on mid-range ejection fraction (mrEF) patients with dilated cardiomyopathy. We sought to
define the characteristics, evolution, and long-term prognosis of dilated cardiomyopathy patients with mrEF at diagnosis.
Methods and Results-—We analyzed all dilated cardiomyopathy patients consecutively evaluated in the Trieste Heart Muscle
Disease Registry from 1988 to 2013. mrEF and reduced ejection fraction (rEF) were defined as baseline left ventricular (LV)
ejection fraction values between 40% and 49% and <40%, respectively. All-cause mortality or heart transplantation, sudden
cardiac death, or major ventricular arrhythmias were considered as outcome measures. Worsening LV ejection fraction (reduction
to <40%) during follow-up was also considered to identify possible predictors of adverse remodeling. Among 812 enrolled
patients, 175 (22%) presented with mrEF at presentation. At baseline, as compared with the rEF group, mrEF patients had lower
rates of moderate–severe mitral regurgitation and restrictive LV filling pattern. During a median follow-up period of 120 (60–204)
months, the mrEF group presented a lower rate of death/heart transplantation (9% versus 36%, P<0.001) and sudden cardiac
death or major ventricular arrhythmias (4.5% versus 15%, P<0.001) than rEF patients. Moreover, 29 out of 175 mrEF patients
(17%) evolved to rEF. Restrictive LV filling pattern emerged as the strongest predictor of rEF development following multivariable
analysis.
Conclusions-—mrEF identified a consistent subgroup of dilated cardiomyopathy patients diagnosed in an earlier stage with
subsequent apparent better long-term evolution. However, 17% of these patients evolved into rEF despite the use of medical
therapy. A baseline restrictive LV filling pattern was independently associated with subsequent evolution to rEF. ( J Am Heart
Assoc. 2019;8:e010705. DOI: 10.1161/JAHA.118.010705.)
Key Words: dilated cardiomyopathy • heart failure • mid-range ejection fraction • prognosis
T he European Society of Cardiology has introduced anovel class of heart failure (HF) without a severely
reduced ejection fraction (EF), calling it as HF with a mid-
range EF. HF with a mid-range EF mainly includes patients
with primarily mild systolic dysfunction and features of
diastolic dysfunction.1 This new entity encompasses
patients with clinical, laboratory, or instrumental evidence
of HF and a left ventricular ejection fraction (LVEF) between
40% and 49%. The definition of this new class of HF could
lead to a better understanding of the characteristics,
pathophysiology, and treatment options for a group of
patients often neglected in randomized clinical trials.1
Dilated cardiomyopathy (DCM), a heterogeneous myocardial
disease with a frequent genetic cause, is characterized by
several degrees of reduced LVEF.2–4 Notably, DCM patients
are typically relatively young, with low comorbidities and
long periods of asymptomatic LV systolic dysfunction.2 They
are often diagnosed in an early phase of the disease,
through the application of extensive genetic counseling
programs and sometimes by way of the results of
preparticipation screenings for sport activities.5,6 Therefore,
at diagnosis, DCM patients could be characterized by the
absence of HF symptoms and non-severe systolic dysfunc-
tion. However, few data on the characteristics, evolution,
and outcomes of DCM patients presenting with mid-range
ejection fraction (mrEF) at baseline are available at this
time.7 In the present study, we sought to characterize DCM
patients presenting with mrEF at baseline, describing their
natural history and prognosis in comparison with reduced
EF (rEF) patients.
From the Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata
di Trieste and University of Trieste, Italy (P.G., M.M., A.C., M. Gobbo, J.A., D.S.,
M. Gigli, F.R., B.P., G.S.); Biostatistics Unit, Department of Medical Sciences,
University of Trieste, Italy (G.B.).
Correspondence to: Merlo Marco, MD, Cardiothoracic Department, Azienda
Sanitaria Universitaria Integrata di Trieste and University of Trieste, Via P.
Valdoni 7, 34100 Trieste, Italy. E-mail: marco.merlo79@gmail.com
Received December 1, 2018; accepted June 26, 2019.
ª 2019 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use, distribu-
tion and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.118.010705 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on August 22, 2019
Methods
The authors declare that all supporting data are available
within the article.
Study Population
All DCM patients consecutively enrolled in the Trieste
Heart Muscle Disease Registry5 from January 1988 to
December 2013 were considered eligible for inclusion in
the present study and were retrospectively analyzed.
Enrolled patients were directly hospitalized in our referral
center or referred shortly after the onset of symptoms
from other centers.
Follow-up ended on December 31, 2015 or at the time of
death or urgent heart transplant (D/HTx).
The institutional ethics board approved the study and
written informed consent was obtained under the institutional
review board policies of the hospital administration.
A diagnosis of DCM was determined according to the
currently accepted criteria.8,9 Ischemic etiology was excluded
with coronary angiography, systematically performed in
patients aged >35 years with cardiovascular risk factors.
Patients with significant coronary artery disease (>50%
stenosis of a major coronary artery), history of severe
systemic hypertension (>160/100 mm Hg), biopsy-proven
active myocarditis, alcohol intake of >100 g/day, significant
organic valve disease, tachycardia-induced cardiomyopathy,
peripartum cardiomyopathy, congenital heart disease, or
advanced systemic disease affecting their short-term prog-
nosis were excluded.5,10,11
After enrollment, if not contraindicated, all patients
received evidence-based pharmacological (at maximum toler-
ated dosages) and device therapies.1
Per protocol, all patients underwent a scheduled follow-up
(clinical and echocardiographic) at 6, 12, and 24 months after
enrollment and then every ≥2 years frequently with respect to
individual clinical necessity.
We divided our population into 2 groups according to the
baseline EF: patients with rEF (ie, EF <40%) and patients with
mrEF (ie, EF 40%–49%).
Table 1. Baseline Clinical Characteristics of the Population
Divided According to LVEF Categories
Total
812 pts
rEF DCM
637 pts
mrEF DCM
175 pts P Value
Age, y 46 (36;56) 48 (37;57) 42 (32;50) 0.001
Male sex (%) 565 (70%) 455 (71%) 110 (63%) 0.029
NYHA III–IV, n (%) 195 (24) 186 (29) 9 (5) <0.001
SBP, mm Hg 12418 12318 12617 0.27
Heart rate, bpm 7816 8016 7012 <0.001
LBBB (%) 256 (32%) 221 (35%) 35 (20%) <0.001
Echocardiography
LAESAI, cm2/m2 144 144 113 <0.001
LVEDDI, mm/m2 366 376 324 <0.001
LVEDVI, mL/m2 9937 10637 7118 <0.001
LVEF, % 3110 277 443 <0.001
RVD, n (%) 199 (26) 182 (30) 17 (10) <0.001
Moderate–severe
MR, n (%)
285 (36) 262 (42) 23 (13) <0.001
Restrictive LV
filling pattern,
n (%)
233 (30) 225 (37) 8 (5) <0.001
E/E0 147 158 103 <0.001
sPAP 3514 3715 255 <0.001
Therapy
ACE-inhibitors-
ARBs, n (%)
783 (96) 624 (98) 159 (91) 0.081
Beta-blockers,
n (%)
729 (90) 576 (91) 153 (88) 0.311
Diuretics, n (%) 607 (75) 531 (84) 76 (44) <0.001
MRAs, n (%) 239 (30) 216 (34) 23 (13) <0.001
Values are expressed asmeanSD ormedian with interquartile range as appropriate, and as
percentage. ACE indicates angiotensin-converting enzyme; ARBs, angiotensin receptor
blockers; LAESAI, left atrial end systolic area indexed; LBBB, left bundle branch block; LV, left
ventricular; LVEDDI, left ventricular end-diastolic diameter indexed; LVEDVI, left ventricular
end-diastolic volume indexed; LVEF, left ventricular ejection fraction; MR, mitral
regurgitation; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart
Association; RVD, right ventricular dysfunction; SBP, systolic blood pressure; sPAP, systolic
pulmonary artery pressure.
Clinical Perspective
What Is New?
• This article includes the largest-to-date patient population
with dilated cardiomyopathy and mid-range ejection fraction
at first presentation.
• Additionally, it provides the first long-term outcome in these
patients with a median follow-up period of 120 (60–204)
months.
What Are the Clinical Implications?
• Patients with mid-range ejection fraction denotes a consis-
tent (ie, 22%) subgroup of dilated cardiomyopathy deserving
careful and reliable risk assessment.
• A non-negligible number of patients (17%) with mid-range
ejection fraction at baseline tend to evolve towards worse
clinical phenotype, with a subsequent worse prognosis.
• The presence of a restrictive left ventricular filling pattern at
baseline might identify those mid-range ejection fraction
patients with a greater risk to experience worse outcomes
during follow-up.
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Outcome Measures
The study analyzed the incidence of the following combined
outcome measures: (1) all-cause mortality and heart trans-
plantation (D/HTx) and (2) sudden cardiac death (SCD) or
major ventricular arrhythmias (MVAs). Specifically, MVAs were
defined as sustained (≥30 seconds, hemodynamically symp-
tomatic) ventricular tachycardia, ventricular fibrillation (VF),
appropriate treatment of sustained ventricular tachycardia or
ventricular fibrillation via implantable cardioverter-defibrillator
therapy (shock or antitachycardia pacing for termination of
sustained ventricular tachycardia ≥185 bpm), or cardiopul-
monary resuscitation after cardiac arrest.12 Finally, a worsen-
ing of LVEF to <40% during follow-up in the group of patients
initially presenting with mrEF was also considered to identify
possible predictors of adverse remodeling.
Echocardiographic Study
Biventricular dimensions and systolic and diastolic functions
were assessed according to international guidelines.13 Specif-
ically, LV volume and LVEF were calculated by the Simpson
biplane method. All volumes were indexed according to body
surface area.
Transmitral E- and A-wave velocities were measured using
pulsed wave Doppler at the level of the mitral leaflet tips. The
LV filling pattern was classified as restrictive in the presence
of an E-wave deceleration time of <120 ms or E/A value ≥2
associated with an E-wave deceleration time of ≤150 ms.14
Right ventricular dysfunction was defined by a right ventric-
ular fractional area change of <35%.15
Mitral regurgitation (MR) was assessed using a multipara-
metric approach applied by measuring the effective regurgi-
tant volume or orifice area as determined by the proximal
isovelocity surface area, whenever feasible, or the vena
contracta width at color-flow Doppler, and graded on a 3-point
scale according to current recommendations.16 Significant
MR was considered if greater than mild.17 Left atrial end-
systolic area was calculated from a 4-chamber view.
All measurements were obtained from the mean of 3 beats
(patients in sinus rhythm) or of 5 beats (patients with atrial
fibrillation).
Statistical Analysis
Summary statistics of clinical and laboratory variables were
expressed as means and standard deviations, medians and
interquartile ranges, or counts and percentages, as appropri-
ate. Cross-sectional comparisons between groups were made
using the ANOVA test on continuous variables, the Brown–
Forsythe statistic when the assumption of equal variances did
not hold, or the non-parametric Mann–Whitney test when
necessary. The chi-squared or Fisher exact test was used for
discrete variables. Repeated measures between baseline and
follow-up were evaluated by means of the paired t test for
continuous Gaussian-distributed parameters or the Wilcoxon
Figure 1. Cumulative incidence curves comparing dilated cardiomyopathy patients with mid-range
ejection fraction and dilated cardiomyopathy patients with reduced ejection fraction in terms of death/
heart transplantation (left) and sudden cardiac death or major ventricular arrhythmias (right). At a median
follow-up of 120 months, as compared with reduced ejection fraction patients, the mid-range ejection
fraction group presented lower rates of all-cause death/heart transplantation (10% vs 30%, P<0.001) and
sudden cardiac death/major ventricular arrhythmias incidence (4% vs 13%, P<0.001). DCM indicates
dilated cardiomyopathy; HTx, heart transplantation; mrEF, mid-range ejection fraction; MVA, major
ventricular arrhythmias; rEF, reduced ejection fraction; SCD, sudden cardiac death.
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test as appropriate. For binary variables, the McNemar test
was applied. Cumulative incidence curves for SCD/MVAs with
respect to the competing risk of death for other causes or
heart transplant were estimated and compared between
groups. Cause-specific uni- and multivariable Cox regression
models were estimated to find factors associated with EF
Figure 2. Cumulative incidence curves comparing dilated cardiomyopathy patients with mid-range
ejection fraction and dilated cardiomyopathy patients with reduced ejection fraction (rEF) in terms of
death/heart transplantation (top panel, A) and sudden cardiac death or major ventricular arrhythmias
(SCD/MVAs) (bottom panel, B), with stratification of the analysis by enrollment period. Lower incidences of
events in terms of all-cause D/HTx and SCD/MVAs were reported in the DCM patients with mrEF
regardless of the time of enrollment (before or after December 31, 2006). ACE indicates angiotensin-
converting enzyme; DCM, dilated cardiomyopathy; HTx, heart transplantation; mrEF, mid-range ejection
fraction; MVA, major ventricular arrhythmias; rEF, reduced ejection fraction; SCD, sudden cardiac death.
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worsening (EF <40%), starting from the list of significant and
clinically relevant parameters that emerged at univariable
analyses and taking into account those with a P value at
univariable analysis of <0.1. Cumulative incidence curves for
the risk of experiencing EF worsening with respect to the
competing risk of death or heart transplant were estimated
and compared between groups, stratified by the presence of
the only significant risk factor derived from the previous
analyses. A time-dependent Cox model was finally estimated
to evaluate the impact of experiencing EF worsening on
survival during follow-up, and an “extended” version of
survival curves was estimated to visually represent results.18
Results
The study population included 812 patients with recently
diagnosed DCM (median duration of symptoms of 2.5 [0–9]
months). One hundred and seventy-five patients (22%)
presented with mrEF (ie, 40%–49%).
At baseline, in comparison with the rEF group, mrEF
patients presented features of a less-advanced stage of
disease, including smaller LV end-diastolic volume, lower
rates of New York Heart Association functional classes III to
IV, left bundle branch block, right ventricular dysfunction,
moderate–severe MR, and restrictive LV filling pattern. No
differences in the administration of angiotensin-converting
enzyme inhibitors and beta-blockers were found; on the
contrary, mrEF patients less frequently took diuretics and
mineralocorticoid receptor antagonists (Table 1).
During a median follow-up time of 120 (60–204) months,
247 patients (30%) died (n=168) or underwent HTx (n=79).
One hundred and five patients (13%) experienced an episode
of SCD (n=59) or had MVAs (n=46). At a median follow-up of
120 months, as compared with the rEF patients, the mrEF
group presented lower rates of all-cause D/HTx (10% versus
30%, P<0.001) and of SCD/MVAs incidence (4% versus 13%,
P<0.001) (Figure 1). A lower incidence of events in terms of
all-cause D/HTx and SCD/MVAs was reported in mrEF
patients than in rEF patients; this was true also upon
stratifying the analysis by enrollment period (ie, before
2006 and from 2007, see Figure 2).
Evolution in rEF
Twenty-nine of 175 mrEF patients (17%) evolved to the rEF
group at a median follow-up of 69 (24–91) months. Patients
with worsened systolic function more frequently showed
restrictive LV filling pattern at baseline in comparison with
patients with persistent mrEF. Consequently, they were more
frequently treated with diuretics and mineralocorticoid
receptor antagonists (Table 2). In the time-dependent Cox
model, DCM patients with persistent mrEF showed a
significantly lower risk of long-term D/HTx than did those
with baseline rEF (considering rEF as the reference category,
hazard ratio: 0.08; 95% CI, 0.03–0.19; Figure 3). Conversely,
DCM patients with mrEF at baseline who, during follow-up,
experienced a shift to rEF status presented a significantly
higher risk of long-term D/HTx than did DCM patients with
baseline rEF (hazard ratio: 2.27; 95% CI, 1.23–4.18;
Figure 3). The presence of a restrictive LV filling pattern
(hazard ratio: 4.0; 95% CI, 1.39–11.57, P=0.01) emerged as
the strongest baseline predictor independently associated
with EF worsening after the stepwise selection starting from
Table 2. Baseline Clinical Characteristics of the mrEF DCM
Group Divided According to Evolution/No Evolution to rEF
(LVEF <40%)
No Evolution to
rEF Group
(n=146)
Evolution to
rEF Group
(n=29) P Value
Age, y 426 4215 0.84
Male sex (%) 91 (62%) 19 (65%) 0.74
NYHA III–IV, n (%) 6 (4) 3 (10) 0.15
SBP, mm Hg 12516 12918 0.17
Heart rate, bpm 6912 7312 0.14
LBBB (%) 29 (19%) 6 (20%) 0.94
Echocardiography
LAESAI, cm2/m2 92 93 0.82
LVEDDI, mm/m2 313 324 0.72
LVEDVI, mL/m2 7018 7015 0.67
LVEF, % 44.12.6 44.33.0 0.70
RVD, n (%) 12 (8) 5 (17) 0.15
Moderate–severe
MR, n (%)
16 (11) 7 (24) 0.057
Restrictive LV filling
pattern, n (%)
4 (2) 4 (14) 0.02
E/E0 103 114 0.11
sPAP 245 295 0.017
Therapy
ACE-inhibitors-ARBs, n (%) 146 (100) 29 (100) 0.34
Beta-blockers, n (%) 127 (88) 26 (88) 0.82
Diuretics, n (%) 58 (40) 18 (62) 0.02
MRAs, n (%) 15 (10) 8 (27) 0.02
Values are expressed as meanSD or median with interquartile range as appropriate,
and as percentage. ACE indicates angiotensin-converting enzyme; ARBs, angiotensin
receptor blockers; LAESAI, left atrial end systolic area indexed; LBBB, left bundle branch
block; LV, left ventricular; LVEDDI, left ventricular end-diastolic diameter indexed;
LVEDVI, left ventricular end-diastolic volume indexed; LVEF, left ventricular ejection
fraction; MR, mitral regurgitation; MRAs, mineralocorticoid receptor antagonists; NYHA,
New York Heart Association; RVD, right ventricular dysfunction; SBP, systolic blood
pressure; sPAP, systolic pulmonary artery pressure.
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the list of significant parameters at univariable analyses
(Table 3 and Figure 4).
Discussion
The existence of patients with mrEF is well-known in clinical
practice. However, these patients have been included in clinical
trials on preserved LVEF by using different EF cutoff values (eg,
>40%, >45%, or >50%), regardless of ischemic or non-ischemic
HF etiology.19–21 Following the introduction of the HFmrEF
class in the last European Society of Cardiology guidelines, the
need for a deeper understanding of this specific subgroup has
been suggested. Nevertheless, recent data reported onHFmrEF
often refer to evaluations in different moments of underlying
disease course.22 Therefore, the real impact of mrEF at the time
of diagnosis of HF is still lacking. Here, we described the natural
history of mrEF from the time of disease presentation in a
recently diagnosed DCM population. This is a strength of the
present study, because limited information is available at this
time in the literature on this subject. DCM patients represent a
particular subgroup of the HF population. In fact, they are
frequently asymptomatic or mildly symptomatic for HF at the
time of diagnosis, often despite severe LV remodeling.2
Asymptomatic DCM patients deserve a careful and reliable
determination of risk, because they could suffer rapid disease
progression or die suddenly early after disease identification.5,8
This study provides a deep insight into the characterization and
natural history of a large and well-selected cohort of DCM
patients presenting with mrEF.
Incidence and Long-Term Outcome of DCM
Patients With mrEF
Our findings show that almost one-quarter of DCM patients
(22%) had mrEF at baseline, with most of them (95%)
presenting with New York Heart Association functional
classes I or II. Similarly, in the CHARM (Candesartan in
Heart Failure: Assessment of Reduction in Mortality and
Morbidity) trial, a consistent quota was found: 1295 of 7955
(17%) HF patients had an LVEF between 43% and 52%.21
Thus, about one-fifth of newly diagnosed HF patients could
present with mrEF, and they should not be neglected.
The main clinical and echocardiographic characteristics at
baseline found in this study indicate that the largest portion of
mrEF DCM patients are diagnosed in a less-advanced stage of
disease. An early diagnosis is probably supported by family
screening programs or results from diagnostic tests per-
formed in subjects being screened for sports participation.6
The resulting early optimal medical treatment probably has
Figure 3. Extended Kaplan–Meier curves. Although dilated cardiomyopathy patients with mid-range
ejection fraction at baseline globally exhibited a better long-term prognosis in comparison with dilated
cardiomyopathy patients with reduced ejection fraction at baseline, the outcome of dilated cardiomyopathy
patients with mid-range ejection fraction who experienced a worsening in their ejection fraction during
follow-up progressively approached and became worse than that of dilated cardiomyopathy patients with
reduced ejection fraction at baseline. DCM indicates dilated cardiomyopathy; HR, hazard ratio; HTX, heart
transplantation; mrEF, mid-range ejection fraction; rEF, reduced ejection fraction
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led to a significantly better prognosis in mrEF patients in
comparison with rEF ones. Nevertheless, the benign progno-
sis of mrEF DCM patients is not generalizable to all cases.
Importantly, a consistent percentage (ie, 17%) of mrEF DCM
patients evolved towards rEF at a median time of 5 years.
There are a subgroup of DCM patients in which mrEF at
presentation represented a transition zone in the way towards
the rEF group. These data highlight the importance of an
adequate early comprehensive characterization and of indi-
vidualized long-term follow-up with recommended treatments
performed in all DCM patients, including those apparently
belonging to low-risk classes. In fact, in previous observa-
tional studies, renin-angiotensin antagonists were associated
with greater benefits in patients with LVEF values of 40% to
49% in comparison with those with values of ≥50%.23 In the
TOPCAT trial (Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist), patients with EF
values of 44% to 50% showed greater benefits when using
spironolactone as compared with those with EF values of
>50%.21 Accordingly, our results expand this information to
application in a DCM subset and encourage clinicians to treat
these patients with full HF therapies despite the absence of
HF symptoms at enrollment, especially in the presence of
diastolic dysfunction.
The Prognostic Role of Diastolic Dysfunction
Our analysis underlines the prognostic role of diastolic
dysfunction in apparently low-risk DCM patients. At first
evaluation, the presence of severe diastolic dysfunction (ie,
restrictive LV filling pattern), associated with non-severe
systolic dysfunction, emerged in our cohort as the strongest
predictor of subsequent EF worsening (Figure 4). Importantly,
patients with mrEF evolving to rEF presented a significantly
higher risk of long-term major events as compared with
baseline rEF patients. As previously reported in patients with
non-dilated hypokinetic cardiomyopathy, the presence of
significant diastolic dysfunction brought to light a subgroup
with a high risk of adverse outcomes.8,10 This similar behavior
could suggest a possible overlap betweenmrEF and non-dilated
hypokinetic cardiomyopathy. A comprehensive and system-
atic genetic characterization, in association with a stricter
follow-up regimen, may be necessary to better characterize
these patients. In fact, a malignant genotype could be
expressed without severe LV remodeling, such as mutations
in LMNA A/C.22 Moreover, a “restrictive” phenotype has been
included in the clinical spectrum of desmin-related cardiomy-
opathies.23
Limitations
Our study population, partially referred to a tertiary center,
along with the retrospective nature of the analysis, may have
Table 3. Univariable Cause-Specific Cox Regression Analysis
for EF Worsening
Unadjusted HRs
HR 95% CI P Value
Age, y 1.009 0.981 to 1.037 0.525
SPB 1.010 0.988 to 1.032 0.368
NYHA III–IV 2.374 0.716 to 7.873 0.158
LBBB 1.172 0.477 to 2.880 0.730
LAESAI 1.041 0.913 to 1.186 0.551
LVEDVI 0.995 0.976 to 1.013 0.563
LVEF 1.031 0.899 to 1.182 0.660
Moderate–severe MR 2.346 1.001 to 5.498 0.050
Restrictive LV
filling pattern*
4.814* 1.662 to 13.947* 0.004*
sPAP 1.191 1.047 to 1.354 0.008
RVD 2.234 0.848 to 5.887 0.104
LAESAI 1.032 0.900 to 1.184 0.650
HR indicates hazard ratio; LAESAI, left atrial end-systolic area indexed; LBBB, left bundle
branch block; LV, left ventricular; LVEDVI, left ventricular end-diastolic volume indexed;
LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart
Association; RVD, right ventricular dysfunction; SBP, systolic blood pressure; sPAP,
systolic pulmonary artery pressure.
*Stepwise Cox regression: starting from a list composed by moderate-severe MR, sPAP,
and a restrictive LV filling pattern; this latter remained the only significant parameter,
with adjusted HR: 2.896; 95% CI, 1.726–15.216; P=0.003 (see Methods section,
Statistical analysis subsection).
Figure 4. Cumulative incidence curves for ejection fraction
worsening of mid-range ejection fraction dilated cardiomyopathy
patients with or without a restrictive left ventricular filling pattern.
The presence of a restrictive left ventricular filling pattern emerged
as the strongest baseline predictor independently associated with
ejection fractionworsening. LV indicates left ventricular; mrEF,mid-
range ejection fraction; rEF, reduced ejection fraction.
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created a degree of selection bias. Our results are applicable
only to DCM patients and should not be generalized to the
whole population of patients with HF. Although the study
population represents, to the best of our knowledge, one of
the largest existing mrEF DCM populations evaluated at
baseline and during follow-up with a complete assessment,
the low number of patients evolving to rEF underpowers the
statistical analysis with only three potential predictors in the
multivariable model. Dosages of medical HF therapy were not
systematically available. However, according to the internal
protocol, all patients uptitrated the therapy to the maximum
tolerated dosage.
Systematic data on natriuretic peptides, 3-dimensional
echocardiography, strain and strain rate, cardiac magnetic
resonance, and genetic characterization findings were not
available. They should be the focus of future larger studies.
Conclusions
mrEF denotes a consistent (ie, 22%) subgroup of DCM
patients who are generally diagnosed in an earlier stage and
who present an apparently better clinical evolution. However,
some mrEF DCM patients evolve into rEF despite medical
therapy, with a subsequently worse prognosis. The presence
of a restrictive filling pattern might be an important clue for
identifying high-risk DCM patients presenting with mrEF.
Disclosures
None.
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